Gabriel Castille

Title: Innovations in Cancer Treatment by Gabriel Castille

Introduction

Gabriel Castille is an accomplished inventor based in Germantown, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic proteins. His work focuses on creating solutions that enhance the efficacy of cancer therapies.

Latest Patents

Gabriel Castille holds a patent for an "Enveloped virus resistant to complement inactivation for the treatment of cancer." This patent describes a recombinant fusion protein that includes a CD55 peptide sequence, a linker sequence, a transmembrane domain, and an intracellular domain. Notably, the fusion protein does not contain a GPI anchor. It can be expressed with an N-terminal secretory signal peptide, which is cleaved to yield the mature protein on the surface of a cell line or an enveloped virus. The oncolytic virus expressing this fusion protein is resistant to complement inactivation, making it a promising candidate for cancer treatment.

Career Highlights

Gabriel Castille is currently associated with Wellstat Immunotherapeutics, LLC, where he continues to advance his research in immunotherapy. His work is pivotal in developing innovative treatments that target cancer cells more effectively.

Collaborations

He collaborates with talented individuals such as Tianci Luo and Rene Molina, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Gabriel Castille's contributions to cancer treatment through his patented innovations highlight the importance of research in developing effective therapies. His work exemplifies the potential of recombinant proteins in advancing medical science.